 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 October 1996 | Volume 125 Issue 7 | Pages 549-557
Background: Uncertainty exists about the efficacy and toxicity of bolus therapy with methylprednisolone or of the combination of methylprednisolone and cyclophosphamide in the treatment of lupus nephritis.
Objective: To determine 1) whether intensive bolus therapy with methylprednisolone is an adequate substitute for bolus therapy with cyclophosphamide and 2) whether the combination of methylprednisolone and cyclophosphamide is superior to bolus therapy with methylprednisolone or cyclophosphamide alone.
Design: Randomized, controlled trial with at least 5 years of follow-up.
Setting: Government referral-based research hospital.
Patients: 82 patients with lupus nephritis who had 10 or more erythrocytes per high-power field, cellular casts, proteinuria (>1 g of protein per day), and a renal biopsy specimen that showed proliferative nephritis.
Interventions: Bolus therapy with methylprednisolone (1 g/m2 body surface area), given monthly for at least 1 year; bolus therapy with cyclophosphamide (0.5 to 1.0 g/m2 body surface area), given monthly for 6 months and then quarterly; or bolus therapy with both methylprednisolone and cyclophosphamide.
Measurements: 1) Renal remission (defined as <10 dysmorphic erythrocytes per high-power field, the absence of cellular casts, and excretion of <1 g of protein per day without doubling of the serum creatinine level), 2) prevention of doubling of the serum creatinine level, and 3) prevention of renal failure requiring dialysis.
Results: Renal remission occurred in 17 of 20 patients in the combination therapy group (85%), 13 of 21 patients in the cyclophosphamide group (62%), and 7 of 24 patients in the methylprednisolone group (29%) (P < 0.001). Twenty-eight patients (43%) did not achieve renal remission. By life-table analysis, the likelihood of remission during the study period was greater in the combination therapy group than in the methylprednisolone group (P = 0.028). Combination therapy and cyclophosphamide therapy were not statistically different. Adverse events were amenorrhea (seen in 41% of the cyclophosphamide group, 43% of the combination therapy group, and 7.4% of the methylprednisolone group), cervical dysplasia (seen in 11% of the cyclophosphamide group, 7.1% of the combination therapy group, and 0% of the methylprednisolone group), avascular necrosis (seen in 11% of the cyclophosphamide group, 18% of the combination therapy group, and 22% of the methylprednisolone group), herpes zoster (seen in 15% of the cyclophosphamide group, 21% of the combination therapy group, and 3.7% of the methylprednisolone group) and at least one infection (seen in 26% of the cyclophosphamide group, 32% of the combination therapy group, and 7.4% of the methylprednisolone group).
Conclusions: Monthly bolus therapy with methylprednisolone was less effective than monthly bolus therapy with cyclophosphamide. A trend toward greater efficacy with combination therapy was seen.
Author and Article Information
From the National Institutes of Health, Bethesda, Maryland.
ARTICLE
Methylprednisolone and Cyclophosphamide, Alone or in Combination, in Patients with Lupus Nephritis
A Randomized, Controlled Trial
Acknowledgments: The authors thank the members of Arthritis and Rheumatism Branch senior staff, medical staff fellows, clinical associates, Clinical Center nursing staff, and the referring physicians, without whose assistance this study would not have been possible.
Grant Support: In part by a fellowship from the Arthritis Foundation (Dr. Gourley).
Requests for Reprints: Mark Gourley, MD, Section of Rheumatology, Washington Hospital Center, 110 Irving Street NW, Washington, DC 20010-2975.
Current Author Addresses: Dr. Gourley: Section of Rheumatology, Washington Hospital Center, 110 Irving Street NW, Washington, DC 20010-2975.
This article has been cited by other articles:
|
|
 |
|
  F. Houssiau and E. Ginzler Current treatment of lupus nephritis Lupus, May 1, 2008; 17(5): 426 - 430. [Abstract] [PDF]
|
|
|
|
|
|
G Bertsias, C Gordon, and D. Boumpas Clinical trials in systemic lupus erythematosus (SLE): lessons from the past as we proceed to the future - the EULAR recommendations for the management of SLE and the use of end-points in clinical trials Lupus, May 1, 2008; 17(5): 437 - 442. [Abstract] [PDF]
|
|
|
|
 |
|
 W. F. Clark and J. M. Sontrop What Have We Learned about Optimal Induction Therapy for Lupus Nephritis (III through V) from Randomized, Controlled Trials? Clin. J. Am. Soc. Nephrol., May 1, 2008; 3(3): 895 - 898. [Full Text] [PDF]
|
|
|
|
 |
|
 G Bertsias, J P A Ioannidis, J Boletis, S Bombardieri, R Cervera, C Dostal, J Font, I M Gilboe, F Houssiau, T Huizinga, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics Ann Rheum Dis, February 1, 2008; 67(2): 195 - 205. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. E. Chen, S. M. Korbet, R. S. Katz, M. M. Schwartz, E. J. Lewis, and for the Collaborative Study Group Value of a Complete or Partial Remission in Severe Lupus Nephritis Clin. J. Am. Soc. Nephrol., January 1, 2008; 3(1): 46 - 53. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Walsh, M. James, D. Jayne, M. Tonelli, B. J. Manns, and B. R. Hemmelgarn Mycophenolate Mofetil for Induction Therapy of Lupus Nephritis: A Systematic Review and Meta-Analysis Clin. J. Am. Soc. Nephrol., September 1, 2007; 2(5): 968 - 975. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Contreras and J. Sosnov Role of Mycophenolate Mofetil in the Treatment of Lupus Nephritis Clin. J. Am. Soc. Nephrol., September 1, 2007; 2(5): 879 - 882. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Zhu, N. Chen, Y. Lin, H. Ren, W. Zhang, W. Wang, X. Pan, and H. Yu Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials Nephrol. Dial. Transplant., July 1, 2007; 22(7): 1933 - 1942. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. C. F. Wilson, D. R. W. Jayne, E. Dellow, and R. J. Fordham The cost-effectiveness of mycophenolate mofetil as firstline therapy in active lupus nephritis Rheumatology, July 1, 2007; 46(7): 1096 - 1101. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Parker and I. Bruce High dose methylprednisolone therapy for the treatment of severe systemic lupus erythematosus Lupus, June 1, 2007; 16(6): 387 - 393. [Abstract] [PDF]
|
|
|
|
|
|
G. G. Illei, C. H. Yarboro, T. Kuroiwa, R. Schlimgen, H. A. Austin, J. F. Tisdale, P. Chitkara, T. Fleisher, J. H. Klippel, J. E. Balow, et al. Long-term effects of combination treatment with fludarabine and low-dose pulse cyclophosphamide in patients with lupus nephritis Rheumatology, June 1, 2007; 46(6): 952 - 956. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Y. Leung, C. C. Szeto, L. S. Tam, C. W. K. Lam, E. K. Li, K. C. Wong, S. W. Yu, and E. W. Kun Urine protein-to-creatinine ratio in an untimed urine collection is a reliable measure of proteinuria in lupus nephritis Rheumatology, April 1, 2007; 46(4): 649 - 652. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F Houssiau Thirty years of cyclophosphamide: assessing the evidence Lupus, March 1, 2007; 16(3): 212 - 216. [Abstract] [PDF]
|
|
|
|
|
|
G Alperovich, I Rama, N Lloberas, M Franquesa, R Poveda, M Goma, I Herrero-Fresneda, J M Cruzado, N Bolanos, M Carrera, et al. New immunosuppresor strategies in the treatment of murine lupus nephritis Lupus, January 1, 2007; 16(1): 18 - 24. [Abstract] [PDF]
|
|
|
|
|
|
A Doria, L Iaccarino, S Arienti, M E Rampudda, M G Canova, R Rondinone, and S Todesco Mycophenolate mofetil and systemic lupus erythematosus Lupus, November 1, 2006; 15(11_suppl): 44 - 54. [Abstract] [PDF]
|
|
|
|
|
|
V Baca, T Catalan, M Villasis-Keever, G Ramon, A. Morales, and F Rodriguez-Leyva Effect of Low-Dose Cyclosporine A in the Treatment of Refractory Proteinuria in Childhood-Onset Lupus Nephritis Lupus, August 1, 2006; 15(8): 490 - 495. [Abstract] [PDF]
|
|
|
|
|
|
G. R. Bihl, M. Petri, and D. M. Fine Kidney biopsy in lupus nephritis: look before you leap Nephrol. Dial. Transplant., July 1, 2006; 21(7): 1749 - 1752. [Full Text] [PDF]
|
|
|
|
|
|
C. Ponticelli New Therapies for Lupus Nephritis Clin. J. Am. Soc. Nephrol., July 1, 2006; 1(4): 863 - 868. [Full Text] [PDF]
|
|
|
|
|
|
C. Grootscholten and J. H. M. Berden Discontinuation of immunosuppression in proliferative lupus nephritis: is it possible? Nephrol. Dial. Transplant., June 1, 2006; 21(6): 1465 - 1469. [Full Text] [PDF]
|
|
|
|
|
|
M A Dooley Mycophenylate mofetil: what role in the treatment of lupus? Lupus, March 1, 2006; 15(3): 179 - 182. [Abstract] [PDF]
|
|
|
|
|
|
J A P Da Silva, J W G Jacobs, J R Kirwan, M Boers, K G Saag, L B S Ines, E J P de Koning, F Buttgereit, M Cutolo, H Capell, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data Ann Rheum Dis, March 1, 2006; 65(3): 285 - 293. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C E. Barber, L Geldenhuys, and J G Hanly Sustained remission of lupus nephritis Lupus, February 1, 2006; 15(2): 94 - 101. [Abstract] [PDF]
|
|
|
|
 |
|
 E. M. Ginzler, M. A. Dooley, C. Aranow, M. Y. Kim, J. Buyon, J. T. Merrill, M. Petri, G. S. Gilkeson, D. J. Wallace, M. H. Weisman, et al. Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis. N. Engl. J. Med., November 24, 2005; 353(21): 2219 - 2228. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. J. McCune Mycophenolate Mofetil for Lupus Nephritis. N. Engl. J. Med., November 24, 2005; 353(21): 2282 - 2284. [Full Text] [PDF]
|
|
|
|
|
|
B Gonzalez, P Hernandez, H Olguin, M Miranda, L Lira, M Toso, A Quezada, X Norambuena, E Talesnik, C Mendez, et al. Changes in the survival of patients with systemic lupus erythematosus in childhood: 30 years experience in Chile Lupus, November 1, 2005; 14(11): 918 - 923. [Abstract] [PDF]
|
|
|
|
 |
|
 D R Smith, B Weinstock-Guttman, J A Cohen, X Wei, C Gutmann, R Bakshi, M Olek, L Stone, S Greenberg, D Stuart, et al. A randomized blinded trial of combination therapy with cyclophosphamide in patients with active multiple sclerosis on interferon beta Multiple Sclerosis, October 1, 2005; 11(5): 573 - 582. [Abstract] [PDF]
|
|
|
|
 |
|
 D. M. Fine Pharmacological Therapy of Lupus Nephritis JAMA, June 22, 2005; 293(24): 3053 - 3060. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T M Chan Lupus nephritis: induction therapy Lupus, March 1, 2005; 14(3_suppl): s27 - s32. [Abstract] [PDF]
|
|
|
|
|
|
G Contreras, E Tozman, N. Nahar, and D. Metz Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide Lupus, March 1, 2005; 14(3_suppl): s33 - s38. [Abstract] [PDF]
|
|
|
|
|
|
C. Gorman, A. Bhatia, and A. Rahman This house believes that low-dose intravenous cyclophosphamide is superior to standard high-dose regimes for treatment of lupus nephritis Rheumatology, March 1, 2005; 44(3): 398 - 401. [Full Text] [PDF]
|
|
|
|
|
|
C C Mok Prognostic factors in lupus nephritis Lupus, January 1, 2005; 14(1): 39 - 44. [Abstract] [PDF]
|
|
|
|
|
|
F A Houssiau Cyclophosphamide in lupus nephritis Lupus, January 1, 2005; 14(1): 53 - 58. [Abstract] [PDF]
|
|
|
|
|
|
T. Chan Lupus nephritis: induction therapy Lupus, January 1, 2005; 14(1_suppl): s27 - s32. [Abstract] [PDF]
|
|
|
|
|
|
G. Contreras, E. Tozman, N. Nahar, and D. Metz Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide Lupus, January 1, 2005; 14(1_suppl): s33 - s38. [Abstract] [PDF]
|
|
|
|
 |
|
 F. A. Houssiau Management of Lupus Nephritis: An Update J. Am. Soc. Nephrol., October 1, 2004; 15(10): 2694 - 2704. [Full Text] [PDF]
|
|
|
|
|
|
S Vasoo First international meeting on mycophenolate mofetil: an advance in the treatment of lupus 27 April 2004, St Thomas' Hospital, London, UK Lupus, July 1, 2004; 13(7): 543 - 545. [PDF]
|
|
|
|
|
|
C.-S. Yee, C. Gordon, A. C. Gelber, L. Christopher-Stine, D. M. Fine, Y. Farhey, E. Hess, G. Contreras, O. Lenz, and D. Roth Sequential Therapies for Proliferative Lupus Nephritis N. Engl. J. Med., June 10, 2004; 350(24): 2518 - 2520. [Full Text] [PDF]
|
|
|
|
|
|
M Petri Cyclophosphamide: new approaches for systemic lupus erythematosus Lupus, May 1, 2004; 13(5): 366 - 371. [Abstract] [PDF]
|
|
|
|
|
|
P I Sidiropoulos and D T Boumpas Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients Lupus, May 1, 2004; 13(5): 391 - 397. [Abstract] [PDF]
|
|
|
|
|
|
C-S Yee, C Gordon, C Dostal, P Petera, J Dadoniene, B Griffiths, B Rozman, D A Isenberg, G Sturfelt, O Nived, et al. EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis Ann Rheum Dis, May 1, 2004; 63(5): 525 - 529. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Contreras, V. Pardo, B. Leclercq, O. Lenz, E. Tozman, P. O'Nan, and D. Roth Sequential Therapies for Proliferative Lupus Nephritis N. Engl. J. Med., March 4, 2004; 350(10): 971 - 980. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L Gonzalez-Lopez, E G Cardona-Munoz, A Celis, I Garcia-de la Torre, G Orozco-Barocio, M Salazar-Paramo, C Garcia-Gonzalez, A Garcia-Gonzalez, A Sanchez-Ortiz, B Trujillo-Hernandez, et al. Therapy with intermittent pulse cyclophosphamide for pulmonary hypertension associated with systemic lupus erythematosus Lupus, February 1, 2004; 13(2): 105 - 112. [Abstract] [PDF]
|
|
|
|
|
|
E Portaccio, V Zipoli, G Siracusa, S Piacentini, S Sorbi, and M P Amato Safety and tolerability of cyclophosphamide 'pulses' in multiple sclerosis: a prospective study in a clinical cohort Multiple Sclerosis, October 1, 2003; 9(5): 446 - 450. [Abstract] [PDF]
|
|
|
|
|
|
C C Mok and C S Lau Lupus in Hong Kong Chinese Lupus, September 1, 2003; 12(9): 717 - 722. [Abstract] [PDF]
|
|
|
|
|
|
C C Mok, R W S Wong, and K N Lai Treatment of severe proliferative lupus nephritis: the current state Ann Rheum Dis, September 1, 2003; 62(9): 799 - 804. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C S Vinen and D B G Oliveira Acute glomerulonephritis Postgrad. Med. J., April 1, 2003; 79(930): 206 - 213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Della Rossa, C. Baldini, A. Tavoni, A. Tognetti, D. Neglia, G. Sambuceti, R. Puccini, C. Colangelo, and S. Bombardieri Churg-Strauss syndrome: clinical and serological features of 19 patients from a single Italian centre Rheumatology, November 1, 2002; 41(11): 1286 - 1294. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. F. Spiera, P. Homel, and H. Spiera Long-Term Outcome in Lupus Nephritis Ann Intern Med, September 17, 2002; 137(6): 545 - 545. [Full Text] [PDF]
|
|
|
|
|
|
H Badsha, K O Kong, T Y Lian, S P Chan, C J Edwards, and H H Chng Low-dose pulse methylprednisolone for systemic lupus erythematosus flares is efficacious and has a decreased risk of infectious complications Lupus, August 1, 2002; 11(8): 508 - 513. [Abstract] [PDF]
|
|
|
|
|
|
D E Gladstone, A A Prestrud, A Pradhan, M J Styler, D L Topolsky, P A Crilley, S Hoch, A Huppert, and I Brodsky High-dose cyclophosphamide for severe systemic lupus erythematosus Lupus, July 1, 2002; 11(7): 405 - 410. [Abstract] [PDF]
|
|
|
|
|
|
G. E. Katsifis, A. G. Tzioufas, P. G. Vlachoyiannopoulos, M. Voulgarelis, H. M. Moutsopoulos, and J. P. A. Ioannidis Risk of myelotoxicity with intravenous cyclophosphamide in patients with systemic lupus erythematosus Rheumatology, July 1, 2002; 41(7): 780 - 786. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. A. Houssiau and M. Jadoul Cytotoxic therapy of lupus nephritis: recent developments Nephrol. Dial. Transplant., June 1, 2002; 17(6): 955 - 957. [Full Text] [PDF]
|
|
|
|
|
|
H L Weiner and J A Cohen Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects Multiple Sclerosis, April 1, 2002; 8(2): 142 - 154. [Abstract] [PDF]
|
|
|
|
|
|
G. G. Illei, H. A. Austin III, M. Crane, L. Collins, M. F. Gourley, C. H. Yarboro, E. M. Vaughan, T. Kuroiwa, C. L. Danning, A. D. Steinberg, et al. Combination Therapy with Pulse Cyclophosphamide plus Pulse Methylprednisolone Improves Long-Term Renal Outcome without Adding Toxicity in Patients with Lupus Nephritis Ann Intern Med, August 21, 2001; 135(4): 248 - 257. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Lewis The Treatment of Lupus Nephritis: Revisiting Galen Ann Intern Med, August 21, 2001; 135(4): 296 - 298. [Full Text] [PDF]
|
|
|
|
|
|
D. Adu The evidence base for the treatment of lupus nephritis in the new millennium Nephrol. Dial. Transplant., August 1, 2001; 16(8): 1536 - 1538. [Full Text] [PDF]
|
|
|
|
|
|
M Mosca, R Neri, S Giannessi, A Pasquariello, R Puccini, W Bencivelli, and S Bombardieri Therapy with pulse methylprednisolone and short course pulse cyclophosphamide for diffuse proliferative glomerulonephritis Lupus, April 1, 2001; 10(4): 253 - 257. [Abstract] [PDF]
|
|
|
|
|
|
K Takada, G G Illei, and D T Boumpas Cyclophosphamide for the treatment of systemic lupus erythematosus Lupus, March 1, 2001; 10(3): 154 - 161. [Abstract] [PDF]
|
|
|
|
|
|
D. A. Isenberg, F. B. Karassa, T. M. Chan, and The Hong Kong-Guangzhou Nephrology Study Group Efficacy of Mycophenolate Mofetil in Patients with Diffuse Proliferative Lupus Nephritis N. Engl. J. Med., February 1, 2001; 344(5): 382 - 383. [Full Text] [PDF]
|
|
|
|
|
|
H Bateman, Y Yazici, L Leff, M Peterson, and S A Paget Increased cervical dysplasia in intravenous cyclophosphamidetreated patients with SLE: a preliminary study Lupus, September 1, 2000; 9(7): 542 - 544. [Abstract] [PDF]
|
|
|
|
|
|
|
Article
